1. Home
  2. ZEPP vs CING Comparison

ZEPP vs CING Comparison

Compare ZEPP & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zepp Health Corporation

ZEPP

Zepp Health Corporation

HOLD

Current Price

$5.16

Market Cap

71.9M

Sector

Technology

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$5.26

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZEPP
CING
Founded
2013
2012
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.9M
64.5M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
ZEPP
CING
Price
$5.16
$5.26
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$34.50
AVG Volume (30 Days)
37.5K
132.2K
Earning Date
05-18-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
56.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$778.34
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.85
$3.16
52 Week High
$61.50
$11.89

Technical Indicators

Market Signals
Indicator
ZEPP
CING
Relative Strength Index (RSI) 51.87 58.37
Support Level $4.04 $5.08
Resistance Level $5.63 $5.54
Average True Range (ATR) 0.36 0.27
MACD 0.11 0.03
Stochastic Oscillator 60.61 82.22

Price Performance

Historical Comparison
ZEPP
CING

About ZEPP Zepp Health Corporation

Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands. Geographically, the group generates revenue from Asia-Pacific, Europe, North America and others.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: